Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A PROBE Clinical Trial

Официальное название

Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A Prospective, Randomized, Parallel-Controlled, Open-Label, Blinded Endpoint (PROBE) Clinical Trial

Обзор

The primary objective of this research is to study the efficacy and safety of daily, home-based hyperthermic baths for reducing epileptic seizures in CDKL5 Deficiency Disorder.

Подробное описание

This is a prospective, randomized, open-label, blinded-endpoint study designed to evaluate the efficacy and safety of daily home-based hyperthermic bathing in participants with CDKL5 deficiency disorder. Eligible participants will be randomized in a 1:1 ratio to receive either hyperthermic baths in addition to usual antiseizure care or usual antiseizure care alone without hyperthermic baths. Efficacy will be assessed primarily by changes in epileptic seizure burden, and safety will be evaluated throughout the study period.

Вмешательства

• Поведенческое Home-based hyperthermic Baths
  A 12-week daily home-based hyperthermic bathing intervention consisting of immersion in a 40-42°C water bath for 20 minutes per session under continuous parental supervision. The intervention will be administered according to the study protocol.

Первичные конечные точки

• Seizure Responder Rate [Срок оценки: Baseline to week 12 at home-based hyperthermic baths phase]

Вторичные конечные точки (2)

• Change in Seizure Frequency [Срок оценки: Baseline to week 12 at home-based hyperthermic baths phase]
• Seizure-free Days [Срок оценки: Baseline to week 12 at home-based hyperthermic baths phase]

Критерии участия

Критерии включения

• A diagnosis of CDKL5 deficiency disorder, including molecular confirmation of a pathogenic CDKL5 variant and exhibiting epileptic seizures.
• Male or female participants aged 6 months to 14 years, inclusive.
• Patients presenting with drug-resistant epilepsy that seizures were uncontrolled despite the appropriate trial of at least two antiseizure medications (ASMs).
• At least 8 motor seizures during each 4 weeks in the 8-week historical seizure records preceding screening.
• Treatment regimens of 0-4 ASMs were required to be stable for at least 4 weeks before screening and throughout the intervention. Ongoing ketogenic diets were allowed if remain unchanged during screening and treatment.
• Subjects who have undergone surgical implantation of vagus nerve stimulation (VNS) will be eligible for inclusion in the study, provided they meet all of the following criteria:

• The VNS device has been in place for at least one year prior to the screening visit;
• The stimulation parameters remain unchanged throughout the duration of the trial.
• Parents or caregivers must be able and willing to maintain an accurate and comprehensive daily electronic seizure diary throughout the duration of the study.
• Participants' legal guardians willing to provide written informed consent.

Критерии исключения

• Patients who had any history of previous brain disease (including trauma, encephalitis, etc.) that were likely to precipitate seizures; defined by MRI outcomes.
• Participants with skin ulceration or dermatologic conditions that make bathing unsuitable.
• Parents or guardians who, based on past experiences, determine that the child has an intolerance to thermal baths.
• A history of seizures induced by thermal baths, or an increase in seizure frequency after thermal baths.
• Patients who presented any clinical condition that in the opinion of the principal investigator made the patient not suitable to participate in the survey.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Простое слепое

Основная цель

Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07602205 · 2026-161-001

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗